RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Other Events
Item 8.01 Other Events.
On March 5, 2019, Ritter Pharmaceuticals, Inc. issued a press release announcing that it has completed enrollment in its first pivotal Phase 3 clincal trial of RP-G28 for the potential treatment of lactose intolerance. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release dated March 5, 2019, entitled Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance |
RITTER PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99-1.htm Exhibit 99.1 Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance Top-line Data Readout Expected in early Q4 2019 LOS ANGELES (March 5,…
To view the full exhibit click here
About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.